Blog Exposure - Cidara Therapeutics Released Positive Top-line Results from Phase-2 STRIVE Trial Assessing its Lead Antifungal Rezafungin
Stock Monitor: BioTime Post Earnings Reporting
LONDON, UK / ACCESSWIRE / March 21, 2018 / Active-Investors.com has just released a free research report on Cidara Therapeutics, Inc. (NASDAQ: CDTX). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CDTX as the Company's latest news hit the wire. On March 19, 2018, the Company announced positive top-line results from the global, randomized Phase-2 STRIVE clinical trial, evaluating the Company's lead antifungal candidate rezafungin acetate, in patients with candidemia and/or invasive candidiasis. Register today and get access to over 1,000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for BioTime, Inc. (NYSE AMER: BTX), which also belongs to the Healthcare sector as the Company Cidara Therapeutics. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/?symbol=BTX
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Cidara Therapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/?symbol=CDTX
STRIVE Met All of its Primary Objectives
STRIVE met all of its primary objectives. The once-weekly intravenous dosing of rezafungin was observed to be generally well tolerated and safe in patients with candidemia and/or invasive candidiasis. The efficacy of rezafungin was demonstrated with the clearance of Candida from the blood or other normally sterile sites, resolution of signs related to the infection, investigator assessment of clinical response, and overall survival. The rezafungin 400mg/200mg regimen (Group 2) had the highest efficacy rate in all assessments. There were no concerning trends in adverse events observed.
Cidara to Initiate Two Phase-3 Clinical Trials of Treatment and Prophylaxis in Mid-2018
Based on the STRIVE trial results, Cidara plans to initiate two Phase-3 clinical trials in mid-2018:
Phase-3 ReSTORE Treatment Trial: A single, global, randomized, double-blind, controlled Phase-3 pivotal clinical trial in approximately 150 mITT patients with candidemia and/or invasive candidiasis. This global Phase-3 trial is expected to generate topline data in 2020.
Phase-3 ReSPECT Prophylaxis (Prevention) Trial: A single, global, randomized, double-blind, controlled Phase-3 pivotal clinical trial in patients undergoing allogeneic bone marrow transplant to enable use of rezafungin in a 90-day prophylaxis regimen to prevent infections due to Candida, Aspergillus, and Pneumocystis. This trial is expected to produce an interim futility read-out in 2019 and provide top-line results in 2020.
FDA Approved Drug for Treatment of Invasive Fungal Infections
In March 2015, the US Food and Drug Administration (FDA) approved Japanese drugmaker Astellas Pharma Inc's anti-fungal drug, Cresemba, for the treatment of two rare, often fatal invasive fungal infections that target patients with blood cancers. Cresemba was approved for use against invasive aspergillosis and invasive mucormycosis. In clinical trials, the drug, also known as isavuconazonium, proved at least as safe and effective in reducing mortality as voriconazole, which Pfizer sells under the brand name Vfend, the standard of care for aspergillosis.
About Invasive Fungal Infections
Invasive fungal infections (IFIs) are a significant health problem in immunocompromised patients. It continues to be a global health issue, especially for critically ill patients in hospitals and patients with compromised immune systems, including cancer and transplant patients. Approximately 90% of IFI-related deaths are associated with Candida, Aspergillus, and Pneumocystis.
About Rezafungin
Rezafungin is a novel antifungal echinocandin being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. Rezafungin is being studied to address unmet needs in treatment of candidemia and invasive candidiasis, and prevention of invasive fungal infections, including Candida, Aspergillus and Pneumocystis. The FDA has designated rezafungin as a Qualified Infectious Disease Product (QIDP) with Fast Track status and orphan drug designation.
The STRIVE Trial
STRIVE is an international, multicenter, double-blind trial evaluating the safety, tolerability and efficacy of once-weekly dosing of rezafungin acetate compared to once-daily dosing of caspofungin in patients with candidemia and/or invasive candidiasis. 92 patients were randomized to one of two rezafungin arms or the comparator arm, in which patients received caspofungin. In the two rezafungin arms of the trial, patients received either 400 mg of rezafungin administered intravenously once weekly for two to four weeks, or 400 mg for the first week followed by 200 mg once weekly for up to four weeks in total. In the comparator arm, patients received daily caspofungin administered intravenously.
About Cidara Therapeutics, Inc.
Founded in 2013 and headquartered in San Diego, California, Cidara Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of various diseases.
Stock Performance Snapshot
March 20, 2018 - At Tuesday's closing bell, Cidara Therapeutics' stock fell 8.33%, ending the trading session at $5.50.
Volume traded for the day: 919.97 thousand shares, which was above the 3-month average volume of 152.44 thousand shares.
After yesterday's close, Cidara Therapeutics' market cap was at $114.79 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.1% at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
